Three days of “The 17th World Chemical Pharmaceutical Ingredient China Exhibition” and “The 12th World Pharmaceutical Machinery, Packaging Equipment and Materials Exhibition of China” (CPhI & P – MEC China 2017) is successfully ended in Shanghai New International Exposition Center recently.According to the statistics, the total exhibition area reach 165,000 square meters, nearly 2800 exhibitors at home and abroad, and have attracted more than 50,000 professional visitors from the pharmaceutical industry, including overseas visitors around 20%.
The exhibits range is very wide in the exhibition, including active pharmaceutical ingredients, intermediates and natural extracts, biological products, pharmaceutical preparations, environmental protection, pharmaceutical packaging, etc. The exhibition is divided into E,W,T,N ,etc.15 zones according to different categories.
What’s particularly noteworthy in this year’s event is Xin Yao (Shenzhen) Biotech Co., Ltd. (hereinafter referred to as Xin Yao Biotech), the exhibitor from the Active Pharmaceutical Ingredients Comprehensive zone, at Booth T5B52, have attracted the favor of domestic and foreign merchants. The author learns that Xin Yao Biotech is an excellent domestic active pharmaceutical ingredients research & development enterprise, but also an agent for standard substance, with its own R&D laboratories, standardized testing laboratories and pharmaceutical research and development team. Xin Yao Biotech have successfully developed apixaban series, cefdinir series, fosaprepitant series, vildagliptin series, minocycline series, saxagliptin series and other impurities in the field of active pharmaceutical ingredients (APIs), among which minocycline, fosaprepitant are recognized as the pain point in the industry.
Since the founding of Xin Yao Biotech, we have established agent cooperation relationship with dozens of pharmacopoeia brands such as EP, USP, BP, TRC, TLC, Chromogenix and MOLCON in the field of standard substance. The next morning of the exhibition, Xin Yao Biotech team have further discussion with Canadian Pharmacopoeia TRC representatives for future cooperation direction, and both sides plan to establish a higher level of technical cooperation in the field of standard substance research & development in the coming year.
The exhibition is successfully ended on the 23th. Xin Yao Biotech demonstrate their independent R&D capability, perfect laboratory equipment and operating system to the customers around the world through the exhibition and win unanimous recognition in the industry. We believe there are even more similar excellent enterprises will get more business opportunities to show their products in the broader international arena through this exhibition.